. Author manuscript; available in PMC: 2013 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2012 Mar 10;18(8):1302–1308. doi: 10.1016/j.bbmt.2012.02.011

Table 2.

Multivariate Analysis Results

Outcome	DR15(+)^*	DR15(−)	P value
Outcome		RR (95% CI)	P value
Acute GVHD B-D^†	1.00	1.02 (0.89–1.16)	.782
Acute GVHD C-D^‡	1.00	0.94 (0.78–1.14)	.548
Chronic GVHD^§	1.00	0.93 (0.81–1.06)	.276
Relapse^\|\|	1.00	1.04 (0.89–1.21)	.612
Overall survival^¶	1.00	1.05 (0.93–1.19)	.441

RR indicates relative risk; CI, confidence interval; GVHD, graft-versus-host disease.

Reference group.

^†

Significant covariates: increasing patient age (P < .0001), cytomegalovirus (CMV) positive recipient (P = .0109), peripheral blood stem cell (PBSC) grafts (P < 0.0001), and Karnofsky performance score <90 (P =.0078).

^‡

Significant covariaties: increasing patient age (P =.0008), PBSC grafts (P =.0003), Karnofsky performance score <90 (P =.0072), and transplantations before 1995 (P =.0038).

^§

Significant covariates: increasing patient age (P < .0001), female donors (P < .0001), and transplantations before 1995 (P =.0136).

^||

Significant covariates: CMV positive recipients (P = .0392) and lymphoid disease (P =.0020).

^¶

Significant covariates: increasing patient age (P < .0001), CMV positive recipients (P=.0136), lymphoid disease (P < .0001), intermediate or advanced disease (P < .0001), PBSC (P =.0014), lower Karnofsky performance score (P < .0001), non-white patients (P = .0058), and transplantations before 1995 (P =.0145).